JNJ-64042056

DRUG2 trials

Sponsors

Janssen - Cilag International, Janssen Pharmaceutica N.V., Belgium

Conditions

Alzheimer DiseasePreclinical Alzheimer’s Disease

Phase 2

A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

Active, not recruitingNCT06544616

Janssen Pharmaceutica N.V., BelgiumAlzheimer Disease

Start: 2024-07-22End: 2026-12-22Updated: 2026-05-13

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer’s Disease

SuspendedCTIS2023-505096-68-00

Janssen - Cilag InternationalPreclinical Alzheimer’s Disease

Start: 2025-01-14Target: 151Updated: 2025-10-30